Disease Landscape and Forecast Insights

The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…

The PsA therapy market is undergoing significant transformation with the emergence of new treatment options, intensifying competition for favorable payer coverage. TNF-α inhibitors, such as AbbVie…

Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PsO for each country, as…

Non-TNF biologics (e.g., IL-17 inhibitors) are gaining momentum in China in the treatment of psoriasis, particularly moderate to severe disease. We expect that the growing psoriasis armamentarium…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of TNF-alpha inhibitors and the IL-12/23 inhibitor ustekinumab (Johnson &…

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…

The treatment of adult psoriasis represents an increasingly lucrative market for biologics for moderate to severe disease, for which conventional systemic and topical treatments are not sufficient…

The arrival of newer and more effective treatments in the U.S. psoriasis market is changing the treatment landscape and fueling competition for favorable coverage from MCOs. After years of…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and the interleukin (IL…

2023 marks a pivotal year for the autoimmune space as numerous releases of biosimilar adalimumab challenge the market dominance of AbbVie’s Humira, one of the best-selling brands in the United…

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management…

Established targeted therapies, such as Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor…